247 related articles for article (PubMed ID: 36463324)
1. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
[TBL] [Abstract][Full Text] [Related]
2. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
3. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract][Full Text] [Related]
4. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
5. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
Wang X; Zhao W; Zhang W; Wu S; Yan Z
J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
[TBL] [Abstract][Full Text] [Related]
6. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway.
Xiao L; Li X; Cao P; Fei W; Zhou H; Tang N; Liu Y
J Exp Clin Cancer Res; 2022 May; 41(1):166. PubMed ID: 35513871
[TBL] [Abstract][Full Text] [Related]
8. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
10. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Cui B; Chen J; Luo M; Liu Y; Chen H; Lü D; Wang L; Kang Y; Feng Y; Huang L; Zhang P
Int J Oral Sci; 2021 Mar; 13(1):8. PubMed ID: 33692335
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma.
Kujan O; Agag M; Smaga M; Vaishnaw Y; Idrees M; Shearston K; Farah CS
Pathology; 2022 Jun; 54(4):409-416. PubMed ID: 34872754
[TBL] [Abstract][Full Text] [Related]
12. Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway.
Li R; Zhou Y; Zhang M; Xie R; Duan N; Liu H; Qin Y; Ma J; Li Z; Ye P; Wang W; Wang X
Int Immunopharmacol; 2023 May; 118():110094. PubMed ID: 37030119
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
Ma SR; Liu JF; Jia R; Deng WW; Jia J
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
[TBL] [Abstract][Full Text] [Related]
14. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract][Full Text] [Related]
15. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Jiang C; Yuan F; Wang J; Wu L
Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
[TBL] [Abstract][Full Text] [Related]
16. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization.
Yuan Y; Jiao P; Wang Z; Chen M; Du H; Xu L; Xu J; Dai Y; Wu FG; Zhang Y; Wu H
Cell Commun Signal; 2022 Jan; 20(1):12. PubMed ID: 35090495
[TBL] [Abstract][Full Text] [Related]
19. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.
Saeed S; Rauf F; Iqbal F; Khan AS; Khan AH; Alamgeer R
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4039-4045. PubMed ID: 36579984
[TBL] [Abstract][Full Text] [Related]
20. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
Kenison JE; Wang Z; Yang K; Snyder M; Quintana FJ; Sherr DH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
